Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.
CEO Laxminarayan Bhat will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" at 8:00 AM ET and will be available for one-on-one meetings with investors throughout the day.
Positive
- None.
Negative
- None.
News Market Reaction – RVPH
In the Oct 2 session, RVPH gained 35.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +67.4% during that session. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 4.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual Roth Healthcare Opportunities Conference, being held on October 9, 2025, in New York, NY.
Roth Healthcare Opportunities Conference
Format: Panel discussion and one-on-one meetings
Panel Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET
To learn more and submit a registration request, click here. Reviva’s management team will be available for one-on-one investor meetings on October 9, 2025.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
